CY1106816T1 - 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση - Google Patents

1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση

Info

Publication number
CY1106816T1
CY1106816T1 CY20071101080T CY071101080T CY1106816T1 CY 1106816 T1 CY1106816 T1 CY 1106816T1 CY 20071101080 T CY20071101080 T CY 20071101080T CY 071101080 T CY071101080 T CY 071101080T CY 1106816 T1 CY1106816 T1 CY 1106816T1
Authority
CY
Cyprus
Prior art keywords
csbp
pyrimidin
compounds
kinase
disubtituted
Prior art date
Application number
CY20071101080T
Other languages
Greek (el)
English (en)
Inventor
Jerry L. Adams
Terri L. Boehm
Ralph F. Hall
John J. Taggart
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of CY1106816T1 publication Critical patent/CY1106816T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
CY20071101080T 2000-03-02 2007-08-13 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση CY1106816T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18641900P 2000-03-02 2000-03-02
PCT/US2001/006688 WO2001064679A1 (en) 2000-03-02 2001-03-02 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases

Publications (1)

Publication Number Publication Date
CY1106816T1 true CY1106816T1 (el) 2012-01-25

Family

ID=22684876

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101080T CY1106816T1 (el) 2000-03-02 2007-08-13 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση

Country Status (25)

Country Link
EP (1) EP1265900B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003525295A (cg-RX-API-DMAC10.html)
KR (1) KR100806978B1 (cg-RX-API-DMAC10.html)
CN (1) CN100482664C (cg-RX-API-DMAC10.html)
AR (2) AR030053A1 (cg-RX-API-DMAC10.html)
AT (1) ATE362473T1 (cg-RX-API-DMAC10.html)
AU (2) AU2001239992B2 (cg-RX-API-DMAC10.html)
BR (1) BR0108715A (cg-RX-API-DMAC10.html)
CA (1) CA2402092C (cg-RX-API-DMAC10.html)
CY (1) CY1106816T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20022933A3 (cg-RX-API-DMAC10.html)
DE (1) DE60128457T2 (cg-RX-API-DMAC10.html)
DK (1) DK1265900T3 (cg-RX-API-DMAC10.html)
ES (1) ES2287107T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0204431A3 (cg-RX-API-DMAC10.html)
IL (3) IL151426A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA02008588A (cg-RX-API-DMAC10.html)
MY (1) MY141144A (cg-RX-API-DMAC10.html)
NO (1) NO326409B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ520914A (cg-RX-API-DMAC10.html)
PL (1) PL358280A1 (cg-RX-API-DMAC10.html)
PT (1) PT1265900E (cg-RX-API-DMAC10.html)
TW (1) TWI290926B (cg-RX-API-DMAC10.html)
WO (1) WO2001064679A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200207017B (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
KR20010043829A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
CA2431904A1 (en) * 2000-12-20 2002-08-01 Merck & Co., Inc. (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
PL212910B1 (pl) 2002-02-12 2012-12-31 Smithkline Beecham Corp Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
KR100608414B1 (ko) 2002-02-13 2006-08-02 에프. 호프만-라 로슈 아게 신규한 피리딘- 및 피리미딘-유도체
JP4603268B2 (ja) * 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR20050111636A (ko) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 피리미도 화합물
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
US20090318424A1 (en) * 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
JP2009542817A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
KR101040394B1 (ko) * 2010-05-18 2011-06-09 (주)이성산업 역화 방지 기능을 갖는 야외용 가스 히터
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
WO2023066283A1 (en) 2021-10-20 2023-04-27 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
PL331602A1 (en) * 1996-08-06 1999-08-02 Pfizer Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
AU4429799A (en) * 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP1123295B1 (en) * 1998-10-23 2004-09-29 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles

Also Published As

Publication number Publication date
CA2402092C (en) 2012-01-24
EP1265900B1 (en) 2007-05-16
EP1265900A1 (en) 2002-12-18
ZA200207017B (en) 2004-02-26
EP1265900A4 (en) 2004-11-10
AU3999201A (en) 2001-09-12
JP2003525295A (ja) 2003-08-26
PL358280A1 (en) 2004-08-09
CN1422273A (zh) 2003-06-04
KR20020082858A (ko) 2002-10-31
NO20024134L (no) 2002-10-24
ATE362473T1 (de) 2007-06-15
CA2402092A1 (en) 2001-09-07
AR030053A1 (es) 2003-08-13
HK1052932A1 (en) 2003-10-03
ES2287107T3 (es) 2007-12-16
AR040075A2 (es) 2005-03-16
IL151426A0 (en) 2003-04-10
TWI290926B (en) 2007-12-11
IL151426A (en) 2011-01-31
IL189865A0 (en) 2008-08-07
WO2001064679A1 (en) 2001-09-07
HUP0204431A1 (hu) 2003-04-28
DE60128457T2 (de) 2008-01-17
CN100482664C (zh) 2009-04-29
MXPA02008588A (es) 2003-02-24
BR0108715A (pt) 2004-04-27
AU2001239992B2 (en) 2005-09-01
NO20024134D0 (no) 2002-08-30
KR100806978B1 (ko) 2008-02-25
DE60128457D1 (de) 2007-06-28
CZ20022933A3 (cs) 2003-02-12
NZ520914A (en) 2004-03-26
MY141144A (en) 2010-03-15
DK1265900T3 (da) 2007-09-24
HUP0204431A3 (en) 2006-01-30
NO326409B1 (no) 2008-12-01
PT1265900E (cg-RX-API-DMAC10.html) 2007-08-22

Similar Documents

Publication Publication Date Title
CY1106816T1 (el) 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
ATE521353T1 (de) Neues trisubstitutiertes 8h-pyridoä2,3- düpyrimidin-7-onderivat zur behandlung von durch csbp/p38kinase vermittelten krankheiten
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
DE60228103D1 (de) Chemische verbindungen
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60209721D1 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
IS7507A (is) Ný efnasambönd
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
SE0302304D0 (sv) Novel compounds
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE60315288D1 (de) Cyanoguanidin prodrugs
ATE381568T1 (de) Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen
UY26498A1 (es) Pirroles sustituidos
HRP20050790A2 (en) New combinations and new use of selected pharmaceutically active compounds
UY26980A1 (es) Nuevos compuestos